Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models (Q39006052)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 April 2014

Language	Label	Description	Also known as
English	Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models	scientific article published on 8 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models (English)

1 reference

Europe PubMed Central

8 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

Emmanuele A. Jannini

8

1 reference

Europe PubMed Central

8 September 2017

Francesco Marampon

object named as

Francesco Marampon

2

0 references

Giovanni Luca Gravina

object named as

Giovanni Luca Gravina

1

0 references

object named as

Andrea Lenzi

7

0 references

author name string

David Sherris

3

1 reference

Europe PubMed Central

8 September 2017

Francesca Vittorini

4

1 reference

Europe PubMed Central

8 September 2017

Ernesto Di Cesare

5

1 reference

Europe PubMed Central

8 September 2017

Vincenzo Tombolini

6

1 reference

Europe PubMed Central

8 September 2017

Claudio Festuccia

9

1 reference

Europe PubMed Central

8 September 2017

publication date

8 April 2014

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

74

1 reference

Europe PubMed Central

8 September 2017

8

1 reference

Europe PubMed Central

8 September 2017

852-868

1 reference

Europe PubMed Central

8 September 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Cyclin D1 in low-dose radiation-induced adaptive resistance.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Inhibition of glycogen synthase kinase 3beta suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Oxidative stress, radiation-adaptive responses, and aging

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Targeting tumor cells by enhancing radiation sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Targeting the Akt-pathway to improve radiosensitivity in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Tumourigenicity and radiation resistance of mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Regulation of protein stability by GSK3 mediated phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Nuclear export is essential for the tumor-promoting activity of survivin.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

A survivin-associated adaptive response in radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22804

21 January 2018

Identifiers

10.1002/PROS.22804

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39006052&oldid=1801965399"